Lachlan Hanbury Brown
Stock Analyst at William Blair
(2.90)
# 2,957
Out of 4,352 analysts
107
Total ratings
44.2%
Success rate
3.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lachlan Hanbury Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Maintained: Buy | n/a | $9.07 | - | 24 | May 15, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | n/a | $9.93 | - | 4 | May 13, 2026 | |
| HROW Harrow | Maintained: Buy | n/a | $35.21 | - | 14 | May 12, 2026 | |
| KLRS Kalaris Therapeutics | Maintained: Buy | n/a | $5.27 | - | 11 | May 12, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | n/a | $7.78 | - | 17 | May 12, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | n/a | $59.40 | - | 10 | May 7, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | n/a | $17.62 | - | 8 | May 5, 2026 | |
| OCUL Ocular Therapeutix | Maintained: Buy | n/a | $9.01 | - | 15 | May 5, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $7.34 | - | 2 | Mar 20, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | n/a | $11.59 | - | 2 | Mar 16, 2026 |
ARS Pharmaceuticals
May 15, 2026
Maintained: Buy
Price Target: n/a
Current: $9.07
Upside: -
Eupraxia Pharmaceuticals Inc.
May 13, 2026
Maintained: Buy
Price Target: n/a
Current: $9.93
Upside: -
Harrow
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $35.21
Upside: -
Kalaris Therapeutics
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $5.27
Upside: -
LENZ Therapeutics
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $7.78
Upside: -
Tarsus Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $59.40
Upside: -
Viridian Therapeutics
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $17.62
Upside: -
Ocular Therapeutix
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $9.01
Upside: -
Solid Biosciences
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $7.34
Upside: -
Zevra Therapeutics
Mar 16, 2026
Maintained: Buy
Price Target: n/a
Current: $11.59
Upside: -